Article Text

Download PDFPDF
Pharmacological interventions
Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram

Statistics from


  • Funding NH has received research support from Lundbeck and Roche.

  • Competing interests NH has received consultation fees from Astellas, Merck and Lilly.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.